# US 12,600,709 B2 · Nonpeptide somatostatin type 5 receptor agonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,600,709 B2
- Document ID: US12600709B2
- Status: Granted
- Kind: B2
- Application number: 18/822,733
- Filed: 2024-09-03
- Published: 2025-05-01
- Granted: 2026-04-14
- Earliest claimed: 2019-08-14
- Assignees: Crinetics Pharmaceuticals, Inc.
- Applicants: Crinetics Pharmaceuticals, Inc.
- Inventors: Jian Zhao; Yunfei Zhu; Shimiao Wang; Mi Chen; Joseph Pontillo
- Web page: https://patentgrep.com/patent/US12600709B2

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 401/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

## Claims

### Claim 1

A method of treating hyperinsulinism in a mammal, the method comprising administering a compound to the mammal in need thereof, wherein the compound is 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1, 1-trifluoropropan-2-yl] pyridine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl] pyridine-3-carboxamide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is a pharmaceutically acceptable salt of 4-[(3S)-3-amino-3-methylpyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl] pyridine-3-carboxamide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hyperinsulinism is congenital hyperinsulinism or drug induced hyperinsulinism.